Skip to main content

Edwards Lifesciences Corp Value Stock - Dividend - Research Selection

Edwards lifesciences

ISIN: US28176E1082 , WKN: 936853

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings and the beating-heart mitral repair systems; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient\'s heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient\'s physiological status; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


3 Medical Instrument Stocks Banking on GenAI to Tackle Industry Woes

2026-02-23
ISRG, EW and ELMD tap GenAI to enhance diagnostics and workflows, even as MedTech faces cost pressures, data risks and macro headwinds.

Podcast: Which pharma and medtech companies came out on top in 2025 revenues?

2026-02-23
The healthcare editorial teams discusses the key trends and growth drivers in companies' recent 2025 financial results.

ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing

2026-02-20
Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s ability to support its valuation.

Top Stock Reports for UnitedHealth, Honeywell & Shopify

2026-02-19
UnitedHealth's earnings beat highlights steady Optum-driven growth, even as rising medical costs and debt pressures keep valuation concerns in focus.

Here's How Much $1000 Invested In Edwards Lifesciences 20 Years Ago Would Be Worth Today

2026-02-19

Edwards Lifesciences to Present at the Barclays and Leerink Partners Global Healthcare Conferences

2026-02-19
IRVINE, Calif., February 19, 2026--Edwards Lifesciences Corporation (NYSE: EW) today announced its chief financial officer, Scott Ullem, is scheduled to present at two upcoming conferences:

Bionic Devices Market Competitor Analysis Report 2025: Recent Developments, Company Strategies, Sustainability Benchmarking, Product Launches, Key Persons, and Revenue Forecasts to 2033

2026-02-18
The global Bionic Devices Market is projected to surge to approximately USD 11.90 billion by 2033, from USD 6.22 billion in 2025, at a CAGR of 8.45%. Key growth drivers include technological advancements in wearable robotics, rising demand for non-invasive treatments, and increasing chronic illnesses. AI innovations and healthcare spending further enhance bionic devices' performance. Leading companies in this field, such as Abbott Laboratories, Abiomed, and Edwards Lifesciences, are driving glob

Exploring the top movers within the S&P500 index during today's session.

2026-02-17
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.

Edwards Lifesciences Corporation (NYSE:EW) is a favorite amongst institutional investors who own 88%

2026-02-16
Key Insights Significantly high institutional ownership implies Edwards Lifesciences' stock price is sensitive to their...

Edwards Lifesciences Corporation (EW) Draws Positive Analyst View After Q4 Update

2026-02-15
Edwards Lifesciences Corporation (NYSE:EW) is one of the best medical technology stocks to invest in. On February 11, Stifel reiterated its Buy rating on Edwards Lifesciences and kept its price target at $110. Stifel made the move right after Edwards Lifesciences shared its Q4 2025 earnings on February 10. The results showed that quarterly sales […]